|
|
Blood, 1 September 2004, Vol. 104, No. 5, pp. 1474-1481.
Prepublished online as a Blood First Edition Paper on May 13, 2004; DOI 10.1182/blood-2004-02-0754.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation
Debes H. Christiansen,
Mette K. Andersen, and
Jens Pedersen-Bjergaard
From the Department of Clinical Genetics, The Chromosome Laboratory, Section of Hematology/Oncology, Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark.
The AML1 transcription factor is essential for normal hematopoiesis and is the target of several chromosomal translocations in acute leukemia. Acquired somatic AML1 mutations were recently demonstrated sporadically in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML) including a few cases of therapy-related disease (t-MDS/t-AML). We examined 140 patients with t-MDS or t-AML for AML1 mutations by direct sequencing. We identified 9 missense, 3 nonsense, and 10 frameshift mutations, all heterozygous, in 22 patients (15.7%). Thirteen mutations were located in the N-terminal Runt homology domain (RHD), whereas 9 mutations were located in the C-terminal region including the transactivation domain (TAD). Nineteen patients with AML1 mutations had previously received alkylating agents whereas 2 patients had received radiotherapy only. AML1 mutations were highly significantly associated with presentation of the disease as t-MDS (P = .003), with deletion or loss of chromosome arm 7q (P = .001) and with subsequent transformation to overt t-AML (P = .0001). Patients with missense mutations presented a shorter survival compared with patients with nonsense/frameshift mutations (P = .03). Our results suggest that AML1 mutations and deletion of genes on chromosome arm 7q cooperate in leukemogenesis and predispose to leukemic transformation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Huang, M. Yu, T. E. Akie, T. B. Moran, A. J. Woo, N. Tu, Z. Waldon, Y. Y. Lin, H. Steen, and A. B. Cantor
Differentiation-Dependent Interactions between RUNX-1 and FLI-1 during Megakaryocyte Development
Mol. Cell. Biol.,
August 1, 2009;
29(15):
4103 - 4115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Kuo, S. K. Zaidi, S. Gornostaeva, T. Komori, G. S. Stein, and L. H. Castilla
Runx2 induces acute myeloid leukemia in cooperation with Cbf{beta}-SMMHC in mice
Blood,
April 2, 2009;
113(14):
3323 - 3332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, J. Wong, M. Klinger, M. T. Tran, K. M. Shannon, and N. Killeen
Mll5 contributes to hematopoietic stem cell fitness and homeostasis
Blood,
February 12, 2009;
113(7):
1455 - 1463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Owen, C. L. Toze, A. Koochin, D. L. Forrest, C. A. Smith, J. M. Stevens, S. C. Jackson, M.-C. Poon, G. D. Sinclair, B. Leber, et al.
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy
Blood,
December 1, 2008;
112(12):
4639 - 4645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Watanabe-Okochi, J. Kitaura, R. Ono, H. Harada, Y. Harada, Y. Komeno, H. Nakajima, T. Nosaka, T. Inaba, and T. Kitamura
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
Blood,
April 15, 2008;
111(8):
4297 - 4308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kirito, K. Sakoe, D. Shinoda, Y. Takiyama, K. Kaushansky, and N. Komatsu
A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies
Haematologica,
January 1, 2008;
93(1):
155 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dicker, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia
Blood,
August 15, 2007;
110(4):
1308 - 1316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, T. Haferlach, W. Kern, C. Haferlach, and S. Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
Haematologica,
June 1, 2007;
92(6):
744 - 752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cammenga, B. Niebuhr, S. Horn, U. Bergholz, G. Putz, F. Buchholz, J. Lohler, and C. Stocking
RUNX1 DNA-Binding Mutants, Associated with Minimally Differentiated Acute Myelogenous Leukemia, Disrupt Myeloid Differentiation
Cancer Res.,
January 15, 2007;
67(2):
537 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
392 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Toedling, S. Schmeier, M. Heinig, B. Georgi, and S. Roepcke
MACAT--microarray chromosome analysis tool
Bioinformatics,
May 1, 2005;
21(9):
2112 - 2113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and A. F. List
Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity
Mayo Clin. Proc.,
May 1, 2005;
80(5):
681 - 698.
[Abstract]
[PDF]
|
|
|
|
|
